Actuate Therapeutics (ACTU) Competitors $6.08 -0.15 (-2.41%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. BCYC, KURA, SEPN, ABVX, MAZE, VALN, BCAX, PGEN, SIGA, and ATYRShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Bicycle Therapeutics Kura Oncology Septerna Abivax Maze Therapeutics Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Bicycle Therapeutics (NASDAQ:BCYC) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Is BCYC or ACTU more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -790.07%. Actuate Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-790.07% -25.54% -21.23% Actuate Therapeutics N/A N/A -339.73% Does the media prefer BCYC or ACTU? In the previous week, Bicycle Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Bicycle Therapeutics and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Bicycle Therapeutics' score of 0.58 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate BCYC or ACTU? Bicycle Therapeutics presently has a consensus target price of $24.22, suggesting a potential upside of 205.45%. Actuate Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 232.25%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, BCYC or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$35.28M15.57-$169.03M-$3.14-2.53Actuate TherapeuticsN/AN/A-$27.28MN/AN/A Do institutionals & insiders believe in BCYC or ACTU? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 69.3% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryActuate Therapeutics beats Bicycle Therapeutics on 7 of the 12 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.86M$2.94B$5.54B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E RatioN/A20.7028.2419.90Price / SalesN/A262.27426.8599.31Price / CashN/A42.3835.5357.53Price / Book617.007.838.265.72Net Income-$27.28M-$55.11M$3.24B$257.71M7 Day Performance-0.16%2.42%0.62%1.06%1 Month Performance-20.59%13.14%8.07%11.27%1 Year PerformanceN/A1.11%27.96%16.81% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.9227 of 5 stars$6.08-2.4%$20.50+237.2%N/A$119.29MN/A0.0010Positive NewsGap UpHigh Trading VolumeBCYCBicycle Therapeutics3.7459 of 5 stars$7.17-3.5%$25.00+248.7%-66.8%$514.56M$35.28M-2.28240News CoverageAnalyst ForecastKURAKura Oncology4.5634 of 5 stars$5.68-3.1%$24.50+331.3%-72.5%$507.33M$53.88M-2.70130SEPNSepterna1.4025 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/AABVXAbivax2.2545 of 5 stars$7.95-0.1%$31.00+289.9%-26.5%$505.10MN/A0.0061News CoveragePositive NewsHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121VALNValneva1.7962 of 5 stars$5.75-1.0%$15.50+169.6%-13.6%$494.40M$183.52M-4.83700Gap DownBCAXBicara Therapeutics1.9948 of 5 stars$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032News CoveragePositive NewsPGENPrecigen4.055 of 5 stars$1.59-1.9%$6.00+277.4%-2.1%$478.19M$4.20M-2.84190Analyst RevisionSIGASiga Technologies1.9841 of 5 stars$6.73+0.6%N/A-26.9%$477.94M$138.72M10.0440ATYRaTyr Pharma2.3061 of 5 stars$5.30-0.2%$20.20+281.1%+235.6%$472.61M$230K-6.5453Gap DownHigh Trading Volume Related Companies and Tools Related Companies BCYC Competitors KURA Competitors SEPN Competitors ABVX Competitors MAZE Competitors VALN Competitors BCAX Competitors PGEN Competitors SIGA Competitors ATYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts